Non Hodgkin Lymphoma And Chronic Lymphocytic Leukemia clinical trials

Explore recruiting non hodgkin lymphoma and chronic lymphocytic leukemia clinical trials.

Recruiting non hodgkin lymphoma and chronic lymphocytic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Hodgkin Lymphoma And Chronic Lymphocytic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

France, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Poland, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL

France, Greece

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Phase I/II Trial to Determine Persistence, Safety and Clinical Activity of Allogeneic CIK Cells Transduced with a Transposon CD19-chimeric Antigen Receptor (CARCIK-CD19) in Adult and Pediatric Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

Poland, Greece, France, Belgium, Spain, Denmark

Human Pharmacology (Phase I)- Other EU CTIS Study details

Non Hodgkin Lymphoma And Chronic Lymphocytic Leukemia trials by city

Non Hodgkin Lymphoma And Chronic Lymphocytic Leukemia clinical trials

Recruiting non hodgkin lymphoma and chronic lymphocytic leukemia studies right now

Personalized NK Cell Therapy in CBT

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Methods of T Cell Depletion Trial (MoTD)

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

Cord Blood Transplant in Adults With Blood Cancers

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Also recruiting in Europe

A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL

Phase I/II Trial to Determine Persistence, Safety and Clinical Activity of Allogeneic CIK Cells Transduced with a Transposon CD19-chimeric Antigen Receptor (CARCIK-CD19) in Adult and Pediatric Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia

An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

Non Hodgkin Lymphoma And Chronic Lymphocytic Leukemia trials by city

Other conditions